Home > Companies > VIVAX BIO / 3D Bioprinting Solutions

VIVAX BIO / 3D Bioprinting Solutions

vivaxbio.com

VIVAX BIO, LLC, based in New York, and its Moscow, Russia, R&D subsidiary, 3D Bioprinting Solutions, focus on 3D bioprinting and work on the whole range of the hardware, materials, technologies, and products comprising the 3D bioprinting industry. We strongly believe that at this stage of the industry development, the synergistic value of integrating the biological and the engineering sides of our business exceeds the potential advantages of specialization.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

8th International Conference on Bio-Sensing Technology

Conference

Related News

MEDGENOME TO INVESTMENT $55M LED BY LEAPFROG INVESTMENTS

Express Healthcare | April 02, 2020

The investment in MedGenome will seek to capitalise on favourable dynamics in both domestic, international markets for genetic diagnostics. MedGenome recently announced an investment of $55m led by LeapFrog Investments. Existing investors Sofina and Sequoia also participated in the round. Sam Santhosh, CEO and Founder, MedGenome said, “Genomics and personalised medicine are the future of healthcare, but emerging markets remain significantly under-penetrated. As the largest player in India ...

Cell and Gene Therapy

ORANGEWOOD PARTNERS MAKES STRATEGIC INVESTMENT IN BARRINGTON JAMES

Orangewood and Barrington James | October 06, 2022

Orangewood Partners a long-term focused private investment firm, announced an investment in Barrington James, a leading global recruitment firm that primarily serves the pharmaceutical, biotechnology and medical device sectors. Terms of the transaction were not disclosed. In partnering with Orangewood, Barrington James intends to enhance its global recruiting solutions, expand its client-service capabilities and support its ongoing commitment to developing and utilizing cutting-ed...

LEXOGEN AND ONRAMP BIOINFORMATICS PARTNER TO PROVIDE DIFFERENTIAL GENE EXPRESSION DATA ANALYSIS AND INTERPRETATION FOR QUANTSEQ 3' MRNA-SEQ USERS

Lexogen | June 17, 2020

Lexogen, a transcriptomics and Next Generation Sequencing company, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis and collaboration tools, announced availability for the QuantSeq 3' mRNA-Seq data analysis pipeline on ROSALIND™, the globally recognized discovery platform for scientists and researchers. The partnership enhances QuantSeq 3' mRNA-Seq data analysis with ROSALIND's visual data exploration and deep pathway interpretation with more than 50 knowle...

BOLT BIOTHERAPEUTICS RAISES $93.5 MILLION SERIES C FINANCING

Bolt Biotherapeutics | July 06, 2020

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the innate immune system to treat cancer, today announced the closing of an oversubscribed $93.5 million Series C financing. Led by Sofinnova Investments, the Series C financing included participation from new investors RA Capital Management, Surveyor Capital (a Citadel Company), Rock Springs Capital, Samsara BioCapital and Pfi...